Type 2 diabetes affects hippocampus volume differentially in men and women

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 1, 2012, Pages 76-83

  Hempel, R ^a   Onopa, R ^a   Convit, Antonio ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Brain complications; Diabetes; Hippocampus; Sex

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DYSLIPIDEMIA; FEMALE; HIPPOCAMPUS; HUMAN; INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SEX DIFFERENCE;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; SEX FACTORS;

EID: 84855410053     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1230     Document Type: Article

References (46)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-1053.
2. Ritz E, Rychlik I, Locatellia F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808.
3. Ikram MK, Janssen JA, Roos AM, et al. Retinal vessel diameters and risk of impaired fasting glucose or diabetes: the Rotterdam study. Diabetes 2006; 55(2): 506-510.
4. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-1134.
5. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006; 60(11): 1471-1483.
6. Barrett-Connor E, Giardina EG, Gitt AK, Gudat U, Steinberg HO, Tschoepe D. Women and heart disease: the role of diabetes and hyperglycemia. Arch Intern Med 2004; 164: 934-942.
7. Crowley A, Menon V, Lessard D, et al. Sex differences in survival after acute myocardial infarction in patients with diabetes mellitus (Worcester Heart Attack Study). Am Heart J 2003; 164(5): 824-831.
8. Natarajan S, Liao Y, Sinha D, Cao G, McGee DL, Lipsitz SR. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med 2008; 165: 430-435.
9. Karame A, Labeeuw M, Trolliet P, et al. The impact of type 2 diabetes on mortality in end-stage renal disease patients differs between genders. Nephron Clin Pract 2009; 112: 268-275.
10. Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984; 311(15): 953-959.
11. Misra R, Lager J. Ethnic and gender differences in psychosocial factors, glycemic control, and quality of life among adult type 2 diabetic patients. J Diabetes Complic 2008; 23: 54-64.
12. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994; 14: 707-720.
13. Cartier A, Côté M, Lemieux I, et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity? Am J Clin Nutr 2009; 89(5): 1307-1314.
14. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5(3): 150-159.
15. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25(1): 4-7.
16. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol 2010; 105: 1284-1288.
17. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119: 2103-2111.
18. Njolstad I, Arnesen E, Lund-Larsen PG. Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark Study. Am J Epidemiol 1998; 147(1): 49-58.
19. Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiologica (Oxford, England) 2010; 198(1): 1-13.
20. Bertoni AG, Burke GL, Owusu JA, et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010; 33(4): 804-810.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001; 286(3): 327-334.
22. McEwen BS. Possible mechanisms for atrophy of the human hippocampus. Mol Psychiatry 1997; 2: 255-263.
23. Ng T, Graham DI, Adams JH, Ford I. Changes in the hippocampus and the cerebellun resulting from hypoxic insults: frequency and distribution. Acta Neuropathologica 1989; 78: 438-443.
24. Kril JJ, Patel S, Harding AJ, Halliday GM. Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. J Neurol Neurosurg Psychiatry 2002; 72(6): 747-751.
25. Gold S, Dziobek I, Sweat V, et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007; 50(4): 711-719.
26. Manschot SM, Brands AM, van der Grond J, et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006; 55(4): 1106-1113.
27. Bruehl H, Wolf OT, Sweat V, Tirsi A, Richardson S, Convit A. Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res 2009; 1280: 186-194.
28. Bruehl H, Wolf OT, Convit A. A blunted cortisol awakening response and hippocampal atrophy in type 2 diabetes mellitus. Psychoneuroendocrinology 2009; 34(6): 815-821.
29. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005; 54(7): 1914-1925.
30. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85(7): 2402-2410.
31. Expert P. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285(19): 2486-2497.
32. De Cristofaro R, Landolfi R. Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations. Blood Coagul Fibrinolysis 1998; 9(3): 251-259.
33. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. Am J Med 1977; 62(5): 707-714.
34. Drake CT, Iadecola C. The role of neuronal signaling in controlling cerebral blood flow. Brain Lang 2007; 102(2): 141-152.
35. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Int Med 2000; 247(4): 425-431.
36. Vinik AI, Erbas T, Park TS, Stansberry KB, Scanelli JA, Pittenger GL, et al. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care 2001; 24(8): 1468-1475.
37. Novak V, Last D, Alsop DC, et al. Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes. Diabetes Care 2006; 29(7): 1529-1534.
38. Petrica L, Petrica M, Vlad A, et al. Cerebrovascular reactivity is impaired in patients with non-insulin-dependent diabetes mellitus and microangiopathy. Wien Klin Wochenschr 2007; 119(11-12): 365-371.
39. Mattson MP, Gurthrie PB, Kater SB. Intrinsic factors in the selective vulnerability of hippocampal pyramidal neurons. Prog Clin Biol Res 1989; 317: 333-351.
40. Man S, Ubogu EE, Ransohoff RM. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol 2007; 17(2): 243-250.
41. Costa MN, Reus VI, Wolkowitz OM, Manfredi F, Lieberman M. Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiatry 1999; 46(2): 182-188.
42. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996; 18(5): 603-606.
43. Czlonkowska A, Ciesielska A, Gromadzka G, Kurkowska-Jastrzebska I. Estrogen and cytokines production-the possible cause of gender differences in neurological diseases. Curr Pharm Des 2005; 11(8): 1017-1030.
44. Arentoft A, Sweat V, Starr V, et al. Plasma BDNF is reduced among middle-aged and elderly women with impaired insulin function: evidence of a compensatory mechanism. Brain Cogn 2009; 71(2): 147-152.
45. Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000; 95(3): 721-725.
46. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabetic Med 2007; 24(4): 333-343.